538 related articles for article (PubMed ID: 33879235)
1. Advances in epigenetic therapeutics with focus on solid tumors.
Jin N; George TL; Otterson GA; Verschraegen C; Wen H; Carbone D; Herman J; Bertino EM; He K
Clin Epigenetics; 2021 Apr; 13(1):83. PubMed ID: 33879235
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation as a target of epigenetic therapeutics in cancer.
Li KK; Li F; Li QS; Yang K; Jin B
Anticancer Agents Med Chem; 2013 Feb; 13(2):242-7. PubMed ID: 22934696
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
4. RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.
Yao L; Yin H; Hong M; Wang Y; Yu T; Teng Y; Li T; Wu Q
Leukemia; 2021 May; 35(5):1243-1257. PubMed ID: 33767371
[TBL] [Abstract][Full Text] [Related]
5. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy.
Chen F; Shi Y; Zhang J; Liu Q
Curr Drug Targets; 2020; 21(11):1084-1098. PubMed ID: 32410563
[TBL] [Abstract][Full Text] [Related]
7. Clinical advances in targeting epigenetics for cancer therapy.
Feng S; De Carvalho DD
FEBS J; 2022 Mar; 289(5):1214-1239. PubMed ID: 33545740
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
Kumar A; Emdad L; Fisher PB; Das SK
Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
Ganesan A; Nolan L; Crabb SJ; Packham G
Curr Cancer Drug Targets; 2009 Dec; 9(8):963-81. PubMed ID: 20025605
[TBL] [Abstract][Full Text] [Related]
10. New anti-cancer strategies: epigenetic therapies and biomarkers.
Balch C; Montgomery JS; Paik HI; Kim S; Kim S; Huang TH; Nephew KP
Front Biosci; 2005 May; 10():1897-931. PubMed ID: 15769674
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
[TBL] [Abstract][Full Text] [Related]
12. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Perez-Plasencia C; Duenas-Gonzalez A
Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies.
Maury E; Hashizume R
Epigenetics; 2017 May; 12(5):353-369. PubMed ID: 28059591
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Therapies and Potential Drugs for Treating Human Cancer.
Lin SQ; Li X
Curr Drug Targets; 2020; 21(11):1068-1083. PubMed ID: 32209040
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets for epigenetic therapy of cancer.
Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
[TBL] [Abstract][Full Text] [Related]
17. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
18. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.
Silverman BR; Shi J
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
20. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
